Do ADHD stimulants affect male fertility?

Bottom line

The first multi-center analysis with a meaningful sample shows stimulant exposure is associated with a modest reduction in semen volume in reproductive-age men with ADHD (~5–8% after adjustment). Sperm concentration, motility, and morphology are unchanged. For ADHD readers on stimulants who are trying to conceive: worth mentioning to your prescriber if timing matters; not a reason to stop a working medication.

The research

Siva and colleagues conducted a retrospective multi-center analysis of men with ADHD aged 18–40 who had an active stimulant prescription (methylphenidate, amphetamine, lisdexamfetamine, dextroamphetamine, or methamphetamine) within 90 days of semen testing. 388 stimulant-exposed men were matched 2:1 to 776 stimulant-unexposed controls, also with ADHD. The matching on age + the ADHD-only comparator is what makes this stronger than prior small single-site studies.

Headline finding: stimulant exposure associated with reduced semen volume — median 2.70 mL vs 2.95 mL, about 8% lower after multivariable adjustment, p=0.01. Sperm concentration, motility, and morphology — the parameters that matter most for fertility — were unchanged. Authors explicitly conclude this is unlikely to meaningfully impair fertility during conception attempts. Funding disclosure: one author is a paid consultant for Tolmar Pharmaceuticals (not a stimulant manufacturer); the reassuring framing doesn’t appear to be driven by the COI.

Caveats. Retrospective design — can’t fully control for unmeasured differences between men who fill stimulant prescriptions and those who don’t. Doesn’t address downstream questions like time to conception or live-birth rates. The direction of effect replicates prior smaller work; the magnitude is best treated as preliminary on the volume parameter and reassuring on the rest.

What this means

If you’re an adult man on stimulants and trying to conceive: the magnitude is small, the parameters that drive fertility weren’t affected, and the authors’ framing is “unlikely to meaningfully impair.” This is a question worth flagging to your prescriber if conception timing is in the next 6–12 months; it’s not a clinical reason to come off a working medication. If you’re seeing a reproductive specialist, bring this paper — they’ll want to know about it, but the data don’t support treatment changes on their own.

Read next on this site:

• Adult ADHD medication walkthrough — the broader side-effect picture; the new finding is now in the sources block.
• Vyvanse vs Adderall — if conception is a planning concern, the choice between stimulant classes hasn’t been shown to matter on this dimension; choose on the dimensions that actually do.
• Menstrual cycle and ADHD medication — the parallel question for the female reproductive system.